List of Devices Companies in Netherlands - 12

AMT Medical is a clinical-stage medical device company based in Ede, Netherlands, with additional facilities in Utrecht. Founded in 2015, the company specializes in developing innovative solutions for cardiac and neurosurgical bypass procedures. Their focus is on transforming bypass surgery through minimally invasive techniques, which include off-pump heart bypass surgery that avoids stopping the heart or fully opening the chest. The company offers a Cardiac Bypass System designed for keyhole and robotic surgery, which has successfully completed First-in-Human trials and is currently undergoing CE certification in Europe. Additionally, AMT Medical has commercialized a Neurosurgical Bypass Device, recognized as a Class III medical device in the EU and U.S., and noted for its life-saving capabilities. With multiple patents protecting their technology, AMT Medical aims to set a new standard in the $15 billion coronary artery disease market, targeting cardiac and neurosurgeons with their advanced solutions.

Angiocare is the only visionary and vibrant medical device partner, that distributes high quality and innovative products through knowledge and passion of our people. To a broad range of healthcare professionals and hospital administrations, who want to work with a trustworthy, do as you say-company bringing added value to a rapid changing healthcare environment with a personal touch. Angiocare is recognized as the no. 1 independent distributor in The Netherlands focusing on diagnostic and interventional therapeutic solutions in the field of Cardiology, (Neuro) Radiology, Vascular Surgery and Interventional Oncology. AngioCare is focusing primarily on cardiovascular solutions and products. We have an international network of innovative suppliers and we often bring new technologies to the Benelux countries. Our experienced sales employees are recognized as "solution bringers" in the emerging field of the mentioned markets and our logistics and order management employees have over 10 years experience in this specialized market segment. Together with our suppliers we have conducted or are conducting registries or trials with new innovative technologies to show clinical benefits for our patients.

ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies and financial support from the Dutch government. The collaboration between the clinical, biomechanical and polymer experts has been instrumental in the development of our Meniscus Prosthesis. Artimis® will be the first anatomically shaped polymer based meniscus implant. Please note, Artimis® is an investigational device in development and is not available for clinical use the coming years. More information can be found on www.atromedical.com

Nordic Pharma is a privately owned, medium-size, fully integrated Pharma company with a history of internal product development and acquisitions. We focus on the development and commercialization of specialty products, which include, but are not limited to, niche hospital and orphan products, to address unmet medical needs. Our expertise relies on the development and sales of our own products, but also on partner products acquired at various stages of development. Today, Nordic Pharma has a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: Rheumatology, Women's Health and Critical Care (Anaesthesia, Haematology, Oncology). We have established deep roots throughout Europe, and more recently, expanded outside of Europe, with the creation of an affiliate in Canada. Our driving force is about innovative and efficient products to fight diseases. We strive to bring solutions to specific unmet medical needs, contributing to improved patient care. Nordic Pharma's values of Commitment, Ambition, Respect, Reliability, Integrity and Agility describe our culture and standards and guide us in our way of working.

ONWARD Medical is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries. ONWARD Medical’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.

Ophtec is a family-owned company founded in 1983 by Prof. Dr. Jan Worst and Anneke Worst-Van Dam. Based in the Netherlands, it is a global leader in intraocular lens (IOL) innovation, specializing in solutions for cataract and refractive surgery. With a focus on pioneering ophthalmic products, Ophtec has recently modernized its brand while celebrating 40 years of excellence in the field. The company offers a range of products, including monofocal, toric, and presbyopia-correcting cataract IOLs, as well as the Artisan lens, the first iris-fixated IOL for refractive correction. Ophtec is also developing new innovations, such as the ArtiPlus lens and pre-loaded injector systems. In addition to its product offerings, Ophtec provides surgeon training and clinical support, collaborating with ophthalmologists to enhance surgical techniques and outcomes. The company is dedicated to empowering eye surgeons to deliver high-quality vision results, particularly in complex cases.

Over the past decade we have transformed into a focused leader in health technology. At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. We aim to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities. We see healthcare as a connected whole. Helping people to live healthily and prevent disease. Giving clinicians the tools they need to make a precision diagnosis and deliver personalized treatment. Aiding the patient's recovery at home in the community. All supported by a seamless flow of data. As a technology company, we – and our brand licensees – innovate for people with one consistent belief: there’s always a way to make life better. Visit our website: http://www.philips.com/ Follow our social media house rules https://www.philips.com/a-w/about-philips/social-media.html

Salvia BioElectronics is pioneering neuromodulation therapy aiming to transform the migraine treatment landscape. Designed to provide meaningful relief, MySalvia Therapy features an ultra-thin implant that comprehensively targets key nerves involved in migraine. ‍Salvia is driven by the belief that people with chronic migraine deserve the opportunity to reclaim their lives. Founded in 2017 and headquartered in Eindhoven, The Netherlands, Salvia is led by a team of industry veterans with extensive experience in medical devices and neuromodulation. Active in the United States, Europe and Australia, the company is advancing clinical development with the support of leading investors. Salvia is also exploring the potential of its technology for the treatment of cluster headache.

Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors. The company is a spin-off of the Netherlands Cancer Institute, where researchers recognized the need to simplify and improve localization technology for the surgical removal of breast cancers. This led to the development and clinical demonstration of the first magnetic seed localization, a technique that Sirius Medical perfected and further developed into the Sirius Pintuition System. Today, Sirius Pintuition represents the next generation of tumor localization technology, known as Surgical Marker Navigation. Pintuition is the only wire-free localization technology designed to provide navigational guidance in an easy-to-use and intuitive system. Its state-of-the-art GPSDetect™ software and unique TargetLOC™ feature provide real-time directional guidance using audio and visual feedback for unmatched precision to locate tumors more efficiently and accurately. The Pintuition platform is simple, precise, and accurate, delivering a better experience for patients and physicians. The CE-marked and FDA-cleared system is currently available in over 200 centers in the United States and western Europe.

Uneedle realises a proprietary microneedle platform "Bella-mu" and "Bella-Vue", co-developing intradermal & suprachoroidal administered medicinal products with pharmaceutical partners. Uneedle is the legal manufacturer of this superior - short lumen - delivery platform. The single, hollow "Uneedles" are FDA approved and CE marked for direct application in the clinics worldwide.

Venus Medtech is a prominent player in transcatheter technologies for structural heart disease therapies. Our comprehensive solutions treat all four heart valves within the human heart (TAVR, TPVR, TMVR, TTVR) in addition to hypertrophic cardiomyopathy, hypertensive renal denervation therapy. Founded in 2009 and headquartered in Hangzhou National High-Tech Industrial Development Zone (Binjiang), the company successfully listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2500.HK) in December 2019. Our journey began with the launch of our first product in 2014, under the New Bioprosthetic Aortic Valve Project in China. We followed this with the introduction of the VenusP-Valve in Europe in 2022. We partner with the top physicians across every continent to understand their challenges and identify opportunities. These insights drive novel breakthrough solutions for a better tomorrow. We invest more than $200M in R&D every year, operate in more than 650 centers worldwide, hold a portfolio of more than 800 patents, and boast a track record of more than 13,000 real-world implantations. As a global leader in the making, Venus Medtech's strategic focus is and will always remain to pioneer innovative technology and equip physicians with the tools they need to enhance the quality of life for patients worldwide.

Vitestro will be the first to bring autonomous blood drawing technology to European hospitals. Blood drawing, performed billions of times per year worldwide, is key to clinical diagnosis. Given a growing population and shortages of healthcare personnel, there is a clear need for a future-proof system to keep up with demand for diagnostics.